Cargando…

IDH1(R132H) Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells

The R132H mutation in isocitrate dehydrogenase 1 (IDH1(R132H)) is commonly observed and associated with better survival in glioblastoma multiforme (GBM), a malignant brain tumor. However, the functional role of IDH1(R132H) as a molecular target for GBM treatment is not completely understood. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Geon-Hee, Choi, So Young, Oh, Taek-In, Kan, Sang-Yeon, Kang, Hyeji, Lee, Sujin, Oh, Taerim, Ko, Hyun Myung, Lim, Ji-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600637/ https://www.ncbi.nlm.nih.gov/pubmed/31151327 http://dx.doi.org/10.3390/ijms20112679

Ejemplares similares

Zerumbone, a Tropical Ginger Sesquiterpene of Zingiber officinale Roscoe, Attenuates α-MSH-Induced Melanogenesis in B16F10 Cells
por: Oh, Taek-In, et al.
Publicado: (2018)

Ursolic Acid Suppresses Cholesterol Biosynthesis and Exerts Anti-Cancer Effects in Hepatocellular Carcinoma Cells
por: Kim, Geon-Hee, et al.
Publicado: (2019)

The prognostic IDH1(R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2010)

HSF1 Regulates Mevalonate and Cholesterol Biosynthesis Pathways
por: Kang, Hyeji, et al.
Publicado: (2019)

Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis
por: Lee, Yoon-Mi, et al.
Publicado: (2019)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing
por: Lee, Jung Hee, et al.
Publicado: (2017)

Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
por: Oh, Se Jin, et al.
Publicado: (2022)

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma
por: Garrett, Matthew C., et al.
Publicado: (2023)

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021)

Computational study on novel natural compound inhibitor targeting IDH1_R132H
por: Zhou, Baolin, et al.
Publicado: (2022)

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss
por: Cai, Hong-Qing, et al.
Publicado: (2018)

Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
por: Kim, Young-Seon, et al.
Publicado: (2018)

Generation and Performance of R132H Mutant IDH1 Rabbit Monoclonal Antibody
por: Rashidian, Juliet, et al.
Publicado: (2017)

Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening
por: Hu, Chujiao, et al.
Publicado: (2022)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma
por: Lu, Jun, et al.
Publicado: (2014)

Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
por: Cuyàs, Elisabet, et al.
Publicado: (2015)

IDH1(R132H) in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis
por: Rosiak, Kamila, et al.
Publicado: (2016)

IDH-1(R132H) mutation status in diffuse glioma patients: implications for classification
por: Wang, Peng-fei, et al.
Publicado: (2016)

Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer
por: Li, Jieying, et al.
Publicado: (2016)

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas
por: Cai, Jinquan, et al.
Publicado: (2016)

Somatic IDH1 variant (p.R132C) in an adult male with Maffucci syndrome
por: Brown, Natasha J., et al.
Publicado: (2021)

R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition
por: Sears, Thomas K., et al.
Publicado: (2022)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma
por: Smith, Jonhoi, et al.
Publicado: (2023)

IDH1-R132 changes vary according to NPM1 and other mutations status in AML
por: Falini, Brunangelo, et al.
Publicado: (2019)

IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway
por: Li, Kaishu, et al.
Publicado: (2017)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
por: Nam, Yoonhee, et al.
Publicado: (2023)

Nanomechanical Signatures in Glioma Cells Depend on CD44 Distribution in IDH1 Wild-Type but Not in IDH1R132H Mutant Early-Passage Cultures
por: Shmelev, Mikhail E., et al.
Publicado: (2023)

Discovery and Validation of Novel LonP1 and Proteasome Inhibitor in IDH1-R132H Malignant Astrocytoma Models
por: Douglas, Christopher, et al.
Publicado: (2023)

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
por: Pellegatta, Serena, et al.
Publicado: (2015)

ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors
por: Cai, Jinquan, et al.
Publicado: (2016)

IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours
por: Mu, Luyan, et al.
Publicado: (2017)

IDH1(R132H) is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment
por: Tiburcio, Patricia D.B., et al.
Publicado: (2018)

Somatic Mosaicism of IDH1 R132H Predisposes to Anaplastic Astrocytoma: A Case of Two Siblings
por: Lee, Sulgi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aap78n70a7vsq92c0cm2n2qqid